Envisagenics Expands Executive Leadership with the Appointment of Sudhir Rao as Chief Business Officer

NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Envisagenics, an AI-driven biotechnology company revolutionizing RNA splicing research and therapeutics, has appointed Sudhir Rao, M.S., MBA as Chief Business Officer (CBO) to expand and strengthen its leadership team. Mr. Rao's extensive leadership in biopharma R&D, business development, alliance management, and strategy will drive Envisagenics' position as a leader in RNA splicing therapeutics and the overall growth of the company.

Mr. Rao brings over 30 years of experience in the life sciences industry, with the last 15 years in business development, spanning both buy side and sell side positions in large pharma and small biotech. He has successfully led and executed numerous high-impact partnerships across oncology, CNS, GI, and immunology therapeutic areas. He has held business positions of increasing responsibility in multiple organizations including most recently being Senior Vice President/Head of Business Development at Expansion Therapeutics, Vice President of Business Development at Genocea Biosciences and Transactions Lead at Takeda Pharmaceuticals.

"We are delighted to welcome Sudhir to Envisagenics," said Maria Luisa Pineda, Ph.D., Envisagenics' co-founder and CEO. "His extensive experience across scientific and business disciplines, combined with his passion for advancing innovative science, will be instrumental for our mission to harness the therapeutic potential of RNA splicing. Sudhir's leadership will help us expand partnerships, bring novel therapies to market, and continue our growth trajectory."

"I am excited to join Envisagenics at this pivotal stage in the company's development," said Mr. Rao. "The company's cutting-edge, AI-driven SpliceCore® platform identifies novel targets, paving the way for innovative treatments in oncology, neurodegenerative diseases, and beyond. I look forward to collaborating with the talented team to execute impactful partnerships, expand our relationships with investors and enable the development of groundbreaking therapies for patients."

For more information about Envisagenics and its leadership team, visit https://envisagenics.com/.

About Envisagenics

Envisagenics is an AI-driven biotechnology company harnessing the therapeutic potential of RNA splicing. Over 95% of human genes undergo alternative splicing, a process generating multiple RNA isoforms from a single gene. Alternative splicing holds the key to understanding and targeting over 370 diseases, including cancer and neurodegenerative disorders. SpliceCore boasts an impressive 400-fold increase in transcriptomic search space compared to conventional tools for target identification. Leveraging our extensive map of over 14 million RNA splicing events, SpliceCore enables the discovery of disease-specific targets, paving the way for the rational design and development of RNA therapeutics and immunotherapies.

Envisagenics collaborates closely with biopharmaceutical companies and academic institutions to elevate their drug discovery capabilities and have previously partnered with the Lung Cancer Initiative at Johnson & Johnson, Biogen, and BMS. Founded in 2014 as a spin-out from Cold Spring Harbor Laboratory, Envisagenics take pride in being a woman- and minority-led organization, with several grants from esteemed institutions like the National Institute of General Medical Sciences and the National Cancer Institute.

For more information on our groundbreaking work, connect with us on Twitter and LinkedIn or visit www.envisagenics.com.

SOURCE Envisagenics, Inc.